Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.

The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.

The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2 kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation.